1. Home
  2. Stocks
  3. Aartipharm Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Aarti Pharmalabs Share Price

    Mid Cap
    ₹664.00
    -12.9 (-1.91%)
    18 September, 2024 02:43 BSE: 543748 NSE: AARTIPHARM ISIN: INE0LRU01027

    Start SIP in Aarti Pharmalabs

    Start SIP

    Aarti Pharmalabs Performance

    Day Range

    • Low 660
    • High 680
    ₹ 664

    52 Week Range

    • Low 371
    • High 722
    ₹ 664
    • Open Price677
    • Previous Close677
    • Volume118887

    Aarti Pharmalabs Chart

    • Over 1 Month + 13.36%
    • Over 3 Month + 9.54%
    • Over 6 Month + 49.5%
    • Over 1 Year + 41.46%

    Aarti Pharmalabs Key Statistics

    P/E Ratio 26.7
    PEG Ratio -1.2
    Market Cap Cr
    Price to Book Ratio 3.4
    EPS 22.1
    Dividend 0.5
    Relative Strength Index 52.22
    Money Flow Index 78.05
    MACD Signal 15.79
    Average True Range 24.97

    Aarti Pharmalabs Investment Rating

    • Master Rating:

    • Aarti Pharmalabs has an operating revenue of Rs. 1,949.75 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 16% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 23% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 45 which is a POOR score indicating inconsistency in earnings, a RS Rating of 62 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 13 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Aarti Pharmalabs Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 393415373356358374
    Operating Expenses Qtr Cr 310307285282281297
    Operating Profit Qtr Cr 8410788747777
    Depreciation Qtr Cr 181717161514
    Interest Qtr Cr 444446
    Tax Qtr Cr 162819121517
    Net Profit Qtr Cr 476348424840
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 1,5131,513
    Operating Expenses Annual Cr 1,1561,203
    Operating Profit Annual in Cr 346308
    Depreciation Cr 6656
    Interest Annual Cr 1720
    Tax Annual Cr 7462
    Net Profit Annual Cr 201172
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 184229
    Cash from Investing Activity Annual Cr -184-116
    Cash from Financing Annual Activity Cr 4-157
    Net Cash Flow Annual Cr 4-43
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,6211,439
    Fixed Assets Annual Cr 1,090950
    Total Non Current Assets Annual Cr 1,1631,004
    Total Current Assets Annual Cr 1,134959
    Total Assets Annual Cr 2,2971,963
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 179159
    ROE Annual % 1212
    ROCE Annual % 1717
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2420
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 555506449440458485
    Operating Expenses Qtr Cr 459388353352373405
    Operating Profit Qtr Cr 9611896888580
    Depreciation Qtr Cr 201919181716
    Interest Qtr Cr 554446
    Tax Qtr Cr 183121151716
    Net Profit Qtr Cr 556553524743
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 1,8581,948
    Operating Expenses Annual Cr 1,4671,603
    Operating Profit Annual in Cr 386342
    Depreciation Cr 7363
    Interest Annual Cr 1721
    Tax Annual Cr 8467
    Net Profit Annual Cr 217193
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 216263
    Cash from Investing Activity Annual Cr -215-158
    Cash from Financing Annual Activity Cr 10-163
    Net Cash Flow Annual Cr 12-58
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 1,7571,558
    Fixed Assets Annual Cr 1,1681,026
    Total Non Current Assets Annual Cr 1,2361,075
    Total Current Assets Annual Cr 1,3461,156
    Total Assets Annual Cr 2,5822,231
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 194172
    ROE Annual % 1212
    ROCE Annual % 1717
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2118
    Invest in Aarti Pharmalabs

    Aarti Pharmalabs Technicals

    EMA & SMA

    Current Price
    ₹664.00
    -12.9 (-1.91%)
    pointer
    • Bullish Moving Average
    • ___
    • 9
    • Bearish Moving Average
    • ___
    • 7
    • 20 Day
    • ₹664.11
    • 50 Day
    • ₹639.27
    • 100 Day
    • ₹606.03
    • 200 Day
    • ₹552.95
    • 20 Day
    • ₹673.26
    • 50 Day
    • ₹631.54
    • 100 Day
    • ₹607.00
    • 200 Day
    • ₹548.43

    Aarti Pharmalabs Resistance and Support

    PIVOT
    ₹668.
    Resistance
    First Resistance 675.65
    Second Resistance 687.30
    Third Resistance 694.95
    RSI 52.22
    MFI 78.05
    MACD Single Line 15.79
    MACD 12.01
    Support
    First Support 656.35
    Second Support 648.70
    Third Supoort 637.05

    Aarti Pharmalabs Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 122,591 6,111,161 49.85
    Week 132,061 6,249,108 47.32
    1 Month 361,733 12,913,852 35.7
    6 Month 362,478 15,347,310 42.34

    Aarti Pharmalabs Result Highlights

    Aarti Pharmalabs Synopsis

    NSE-Medical-Ethical Drugs

    Aarti Pharmalabs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1502.13 Cr. and Equity Capital is Rs. 45.31 Cr. for the Year ended 31/03/2024. Aarti Pharmalabs Ltd. is a Public Limited Listed company incorporated on 22/11/2019 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24100GJ2019PLC110964 and registration number is 110964.
    Market Cap 6,134
    Sales 1,537
    Shares in Float 4.89
    No of funds 114
    Yield 0.44
    Book Value 3.78
    U/D Vol ratio 1.7
    LTDebt / Equity
    Alpha 0.04
    Beta 1.28

    Aarti Pharmalabs Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 46.46%46.46%46.46%46.3%
    Mutual Funds 4.69%2.72%2.05%2.67%
    Insurance Companies 6.09%6.49%7.03%7.03%
    Foreign Portfolio Investors 7.07%8.33%8.17%8.45%
    Financial Institutions/ Banks 0.02%0.02%0.02%
    Individual Investors 29.57%29.71%29.73%29.13%
    Others 6.12%6.27%6.54%6.4%

    Aarti Pharmalabs Management

    Name Designation
    Mr. Chandrakant Vallabhaji Gogri Chairman Emeritus
    Mr. Rashesh C Gogri Chairman
    Mrs. Hetal Gogri Gala Vice Chairperson & M.D
    Mr. Narendra J Salvi Managing Director
    Mr. Rajendra V Gogri Non Executive Director
    Mr. Parimal H Desai Non Executive Director
    Ms. Nehal Garewal Non Executive Director
    Mr. Bhavesh R Vora Independent Director
    Mrs. Jeenal K Savla Independent Director
    Mrs. Rupal A Vora Independent Director
    Mr. Vilas Gajanan Gaikar Independent Director
    Dr. Vinay G Nayak Independent Director
    Mr. Pradeep H Thakur Independent Director

    Aarti Pharmalabs Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Aarti Pharmalabs Corporate Action

    Date Purpose Remarks
    2024-08-05 Quarterly Results
    2024-05-13 Audited Results & Final Dividend
    2024-02-07 Quarterly Results & Interim Dividend
    2023-11-07 Quarterly Results
    2023-08-05 Quarterly Results
    Date Purpose Remarks
    2024-07-31 FINAL Rs.1.00 per share(20%)Final Dividend
    2024-02-19 INTERIM Rs.2.00 per share(40%)Interim Dividend

    Aarti Pharmalabs MF Shareholding

    Name Amount(cr)
    Quant Small Cap Fund Growth 25,535
    HDFC Large and Mid Cap Fund Growth 23,712
    Aditya Birla Sun Life Flexi Cap Fund Growth 23,228
    HDFC Multi Cap Fund Regular Growth 17,186
    Quant Flexi Cap Fund Growth 7,710

    Aarti Pharmalabs FAQs

    What is Share Price of Aarti Pharmalabs ?

    Aarti Pharmalabs share price is ₹664 As on 18 September, 2024 | 02:29

    What is the Market Cap of Aarti Pharmalabs ?

    The Market Cap of Aarti Pharmalabs is ₹6017.6 Cr As on 18 September, 2024 | 02:29

    What is the P/E ratio of Aarti Pharmalabs ?

    The P/E ratio of Aarti Pharmalabs is 26.7 As on 18 September, 2024 | 02:29

    What is the PB ratio of Aarti Pharmalabs ?

    The PB ratio of Aarti Pharmalabs is 3.4 As on 18 September, 2024 | 02:29

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.